Voloridge Investment Management
RPRX icon

Voloridge Investment Management’s Royalty Pharma RPRX Stock Holding History

Voloridge Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.95M Buy
+52,561
New +$2.74M 0.01% 615
2026
Q1 		– Sell
-100,528
Closed -$3.88M – 1240
2025
Q4 		$3.88M Buy
+100,528
New +$3.83M 0.01% 809
2024
Q1 		– Sell
-24,524
Closed -$689K – 1327
2023
Q4 		$689K Sell
24,524
-48,583
-66% -$1.34M ﹤0.01% 991
2023
Q3 		$1.98M Sell
73,107
-309,622
-81% -$9.2M 0.01% 923
2023
Q2 		$11.8M Sell
382,729
-55,272
-13% -$1.87M 0.06% 423
2023
Q1 		$15.8M Sell
438,001
-11,290
-3% -$419K 0.08% 334
2022
Q4 		$17.8M Buy
+449,291
New +$18.8M 0.1% 290
2021
Q4 		– Sell
-11,195
Closed -$405K – 1812
2021
Q3 		$405K Sell
11,195
-58,710
-84% -$2.28M ﹤0.01% 1495
2021
Q2 		$2.87M Buy
+69,905
New +$2.97M 0.02% 852

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Voloridge Investment Management's RPRX Position: Q2 2026 in Review

Voloridge Investment Management opened a new position in Royalty Pharma (RPRX) in Q2 2026: 52,561 shares worth $2.95M. The stake represents 0.01% of the portfolio and ranks #615 among its holdings. This is a return to the name: Voloridge Investment Management previously reported a position in RPRX as recently as Q4 2025.

Voloridge Investment Management first reported a position in RPRX in Q2 2021 and has held it in 9 quarters since. The position peaked at $17.8M in Q4 2022. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Voloridge Investment Management held 52,561 shares of Royalty Pharma worth $2.95M as of Q2 2026.
  • Royalty Pharma was a new Voloridge Investment Management position in Q2 2026.
  • Royalty Pharma made up 0.01% of Voloridge Investment Management's portfolio in Q2 2026, its #615 holding.
  • Voloridge Investment Management first reported a position in Royalty Pharma in Q2 2021 and has held it in 9 quarters since.
  • Voloridge Investment Management's Royalty Pharma position peaked at $17.8M in Q4 2022.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Voloridge Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.